Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDIGO: Atezolizumab and Tiragolumab in TLS-positive Advanced NSCLC
NCT06713798Phase 2Withdrawn
- Sponsor
- Gustave Roussy
- Start
- Jan 2025
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of tiragolumab in non-small cell lung cancer (NSCLC), sponsored by Gustave Roussy. Planned start Jan 2025; status: withdrawn.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06713798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06713798.